The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Open accessAbstract
IMPORTANCE: Several studies have reported antidepressant effects of anti-inflammatory treatment; however, the results have been conflicting and detrimental adverse effects may contraindicate the use of anti-inflammatory agents. OBJECTIVE: To systematically review the antidepressant and possible adverse effects of anti-inflammatory interventions. DATA SOURCES: Trials published prior to December, 31, 2013, were identified searching Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO, Clinicaltrials.gov, and relevant review articles. STUDY SELECTION: Randomized placebo-controlled trials assessing the efficacy and adverse effects of pharmacologic anti-inflammatory treatment in adults with depressive symptoms, including those who fulfilled the criteria for depression. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 independent reviewers. Pooled standard mean difference (SMD) and odds ratios (ORs) were calculated. MAIN OUTCOMES AND MEASURES: Depression scores after treatment and adverse effects. RESULTS: Ten publications reporting on 14 trials (6262 participants) were included: 10 trials evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (n=4,258) and 4 investigated cytokine inhibitors (n=2,004). The pooled effect estimate suggested that anti-inflammatory treatment reduced depressive symptoms (SMD, -0.34; 95% CI, -0.57 to -0.11; I2=90%) compared with placebo. This effect was observed in studies including patients with depression (SMD, -0.54; 95% CI, -1.08 to -0.01; I2=68%) and depressive symptoms (SMD, -0.27; 95% CI, -0.53 to -0.01; I2=68%). The heterogeneity of the studies was not explained by differences in inclusion of clinical depression vs depressive symptoms or use of NSAIDs vs cytokine inhibitors. Subanalyses emphasized the antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, -0.29; 95% CI, -0.49 to -0.08; I2=73%) on remission (OR, 7.89; 95% CI, 2.94 to 21.17; I2=0%) and response (OR, 6.59; 95% CI, 2.24 to 19.42; I2=0%). Among the 6 studies reporting on adverse effects, we found no evidence of an increased number of gastrointestinal or cardiovascular events after 6 weeks or infections after 12 weeks of anti-inflammatory treatment compared with placebo. All trials were associated with a high risk of bias owing to potentially compromised internal validity. CONCLUSIONS AND RELEVANCE: Our analysis suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks of adverse effects. However, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof-of-concept concerning the use of anti-inflammatory treatment in depression. Identification of subgroups that could benefit from such treatment might be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who receive cytokine treatments such as IL-2 or IFN γ as part of their treatment for hepatitis or cancer often develop depressive symptoms 82”
From Major depressive disorder (2016) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Kohler and colleagues found that patients prescribed celecoxib compared to placebo were 7 times more likely to respond to an antidepressant with no increased risks of GI or CV effects (155).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“blockade of cytokines, such as TNF, or of inflammatory signalling pathway components, such as cyclooxygenase 2, has been shown to reduce depressive symptoms in patients with medical illnesses, including rheumatoid arthritis, psoriasis and cancer, as well as in patients with major depressive disorder27–29.”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, it appears that anti-inflammatory agents may only demonstrate effective antidepressant activity in subgroups of patients who show evidence of increased peripheral inflammation, for example individuals with medical conditions including osteoarthritis and psoriasis that are characterized by increased levels of peripheral inflammation and patients with depression with increased”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“depressive symptoms are more frequent in patients with conditions involving inflammation (e.g., autoimmune diseases) and can be reversed through the use of anti-inflammatory drugs (Kojima et al., 2009; Köhler et al., 2014).”
From The interplay between stress, inflammation, and emotional attention: relevance for depression (2019) · cites this paper as Köhler et al., 2014
In the citing paper
“There is also meta-analytic evidence that anti-inflammatory treatments can be effective means for treating depression (Köhler et al., 2014).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Köhler et al., 2014
In the citing paper
“A meta-analysis of nonsteroidal anti-inflammatory drugs and cytokine inhibitors suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms in individuals with major depression or with clinically significant depressive symptoms198.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [198]
In the citing paper
“There is particular interest in how inflammatory cell types in the brain cause depressive symptoms, as anti-inflammatory treatments reduce depressive symptoms in humans [173] and chronic stress enhances inflammation in animal models [174].”
From The molecular and cellular mechanisms of depression: a focus on reward circuitry (2019) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Gluud, L. L., Villumsen, J., & Gluud, C. N. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,266
The case of the misleading funnel plot
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006) · BMJ · doi:10.1136/bmj.333.7568.597 · Cited by 1,766
Research works printed but not linked: 2
- [24]24. Raison C, Rutherford RE, Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2012;26(suppl 1):S49. doi:10.1016/j.bbi.2012.07.200.W. · DOI
- [27]27. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bul. 2011;21:S183-S184.
Cited by
Sorted by citations
Items 501–600 of 942
Köhler-Forsberg, O., Sylvia, L., Deckersbach, T., Ostacher, M. J., McInnis, M., Iosifescu, D., Bowden, C., McElroy, S., Calabrese, J., Thase, M., et al. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.34 · Cited by 15
C-Reactive Protein (CRP): A Potent Inflammation Biomarker in Psychiatric Disorders
Orsolini, L., Pompili, S., & Volpe, U. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_7 · Cited by 19
Shan, M., Yang, Z., Sun, Z., Yang, Y., Cheng, Q., & Pan, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20127 · Cited by 16
Sokołowska, P., Bleibel, L., Owczarek, J., & Wiktorowska‐Owczarek, A. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/174243 · Cited by 17
Ni, J., Wu, P., Xiaofeng, L., & Xu, C. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05878-x · Cited by 16
Ghrelin, Neuroinflammation, Oxidative Stress, and Mood Disorders: What Are the Connections?
Mingardi, J., Meanti, R., Paoli, C., Cifani, C., Torsello, A., Popoli, M., & Musazzi, L. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22999240722095039 · Cited by 16
Sick and Tired: Mood, Fatigue, and Inflammation in Cancer
Kruse, J. L., & Strouse, T. B. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0555-3 · Cited by 16
Köhler‐Forsberg, O., Petersen, L. V., Benros, M. E., Mors, O. N., & Gasse, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1168400 · Cited by 16
Self-citationAlboni, S., Benatti, C., Capone, G., Tascedda, F., & Brunello, N. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.063 · Cited by 16
Psychoneuroimmunology of mental disorders
Soria, V., Uribe, J., Salvat‐Pujol, N., Palao, D. J., Menchón, J. M., & Labad, J. (2018) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2017.07.002 · Cited by 17
Disease severity across psychiatric disorders is linked to pro-inflammatory cytokines
Solomon, P., Budde, M., Kohshour, M. O., Adorjan, K., Heilbronner, M., Navarro‐Flores, A., Papiol, S., Reich‐Erkelenz, D., Schulte, E. C., Senner, F., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.06.004 · Cited by 18
McFarland, D. C., Applebaum, A. J., Bengtsen, E. H., Alici, Y., BREITBART, W. S., Miller, A. H., & Nelson, C. J. (2021) · Psycho-Oncology · doi:10.1002/pon.5811 · Cited by 15
Businaro, R. (2022) · F1000Research · doi:10.12688/f1000research.75856.1 · Cited by 16
Shan, M., Lü, S., Cui, R., Yang, Y., Sun, Z., & Pan, Y. (2022) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2022.111041 · Cited by 15
Biomarkers of stress resilience: A review
Paribello, P., Branchi, I., Viglione, A., Mancini, G. F., Morena, M., Campolongo, P., & Manchia, M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104052 · Cited by 17
An intricate relationship between circadian rhythm dysfunction and psychiatric diseases
Samanta, S., & Bagchi, D. (2024) · Exploration of neuroscience · doi:10.37349/en.2024.00053 · Cited by 16
Network analysis of depressive symptoms and C-reactive protein levels in major depressive disorder
Wang, D., Xu, J., Liang, N., Xue, Z., Yang, X., Lu, J., & Ma, Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.152 · Cited by 15
Association between parity and female mortality: the mediative role of depressive symptoms
Deng, Z., Wei, Y., Dai, F., Yang, D., Tang, D., Liu, J., & Yin, T. (2024) · Human Reproduction · doi:10.1093/humrep/deae196 · Cited by 15
Gao, Y., Pan, K., Zhang, Y.-M., Qi, Y., Chen, W.-G., Zhou, T. J., Zong, H.-C., Guo, H., Zhao, J.-W., Liu, X., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01384-8 · Cited by 18
Kinderlehrer, D. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s500337 · Cited by 15
Talmon, M., Chaudhari, R. D., Suryavanshi, H., Chowdhury, N., Quaregna, M., Pin, A., Bagchi, A., Biswas, G. K., & Fresu, L. G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115760 · Cited by 15
Hmamou, A., El-Assri, E.-M., Khomsi, M. E., Kara, M., Alshawwa, S. Z., Kamaly, O. M. A., oumari, F. E. E., Eloutassi, N., & Lahkimi, A. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.06.019 · Cited by 15
Aspirin and incident depressive symptoms: A longitudinal cohort study over 8 years
Veronese, N., Koyanagi, A., Stubbs, B., Solmi, M., Fornaro, M., Fernandes, B. S., Müller, C., Thompson, T., Carvalho, A. F., & Maggi, S. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4767 · Cited by 15
New medications for treatment-resistant depression: a brief review of recent developments
Thase, M. E. (2017) · CNS Spectrums · doi:10.1017/s1092852917000876 · Cited by 15
Antenatal depression, psychotropic medication use, and inflammation among pregnant women
Miller, E. S., Grobman, W. A., Culhane, J. F., Adam, E. K., Buß, C., Entringer, S., Miller, G. E., Wadhwa, P. D., Keenan‐Devlin, L. S., & Borders, A. E. B. (2018) · Archives of Women s Mental Health · doi:10.1007/s00737-018-0855-9 · Cited by 16
Genetic comorbidity of depression and somatic disorders
Rukavishnikov, G. V., Kibitov, A. O., Mazo, G. E., & Незнанов, Н. Г. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201911901189 · Cited by 16
Köhler‐Forsberg, O., Sylvia, L. G., Thase, M. E., Calabrese, J. R., Deckersbach, T., Tohen, M. F., Bowden, C. L., McInnis, M. G., Kocsis, J. H., Friedman, E. S., et al. (2017) · Depression and Anxiety · doi:10.1002/da.22601 · Cited by 15
Kavakbasi, E., Sampson, E., Mills, N. T., Hori, H., Schwarte, K., Hohoff, C., Schubert, K. O., Clark, S. R., Fourrier, C., & Baune, B. T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15946 · Cited by 19
Sampson, E., Mills, N. T., Hori, H., Cearns, M., Schwarte, K., Hohoff, C., Schubert, K. O., Fourrier, C., & Baune, B. T. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.09.003 · Cited by 16
Inflammation and Depression: the Neuroimmune Connection
Toups, M. S. P. (2018) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-018-0157-x · Cited by 13
Choi, J. H., Lee, M. J., Chang, Y., Lee, S., Kim, H., Lee, S., Kim, Y. O., & Cho, I. (2019) · Rejuvenation Research · doi:10.1089/rej.2018.2157 · Cited by 14
Holtdirk, F., Mehnert-Theuerkauf, A., Weiss, M., Meyer, B., & Watzl, C. (2020) · Trials · doi:10.1186/s13063-019-3987-y · Cited by 14
Immunoinflammatory processes: Overlapping mechanisms between obesity and eating disorders?
Breton, É., Soh, J. F., & Booij, L. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104688 · Cited by 15
Mapping the structure of depression biomarker research: A bibliometric analysis
Guo, X., Wu, P., Jia, X. P., Dong, Y., Zhao, C., Chen, N., Zhang, Z., Miao, Y.-T., Yun, K., Gao, C., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.943996 · Cited by 14
Chen, Y., Wang, E. J., Sites, B. D., & Cohen, S. P. (2023) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2022-104203 · Cited by 13
Wang, M., Jin, G., Cheng, Y., Guan, S., Zheng, J., & Zhang, S.-X. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1242614 · Cited by 13
Chen, B., Pu, B., Li, S., Gong, Y., & Dong, H. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.121 · Cited by 14
Kurbatfinski, S., Dosani, A., Dewey, D., & Letourneau, N. L. (2024) · Children · doi:10.3390/children11091112 · Cited by 16
Is There such a Thing as Post-Viral Depression?: Implications for Precision Medicine
Park, E., Shin, C. Y., Jeon, S. J., & Ham, B. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.170 · Cited by 14
Troyer, E. A., Kohn, J. N., Ecklu-Mensah, G., Aleti, G., Rosenberg, D. R., & Hong, S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.034 · Cited by 15
Fraga-Junior, E. B., Fernandes, I. L., Rohden, C. A. H., Doneda, D. L., Ynoue, H. N., Rios-Santos, F., Lima, E., Buss, Z. S., & Vandresen-Filho, S. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.014 · Cited by 14
The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs
Markov, D. D., Dolotov, O. V., & Grivennikov, I. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076664 · Cited by 14
von Mücke-Heim, I.-A., Martin, J. N., Uhr, M., Ries, C., & Deussing, J. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1148190 · Cited by 16
Molero, P., Ruiz-Estigarribia, L., Lahortiga‐Ramos, F., Sánchez‐Villegas, A., Bes‐Rastrollo, M., Escobar-González, M., Martínez‐González, M. Á., & Fernández‐Montero, A. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.01.020 · Cited by 13
Abdoli, A., & Ardakani, H. M. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00466-5 · Cited by 13
Toft, H., Lien, L., Neupane, S. P., Abebe, D., Tilden, T., Wampold, B. E., & Bramness, J. G. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.36 · Cited by 13
Mohamed, A. E., El-Latif, R. A., Youssef, A. M., & Ibrahim, A. (2020) · Middle East Current Psychiatry · doi:10.1186/s43045-020-00038-9 · Cited by 12
Neuropsychiatric disorders: An immunological perspective
Aw, E., Zhang, Y., Yalçın, E., Herrmann, U., & Carroll, M. C. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.09.002 · Cited by 13
The complicated relationship between inflammation and metabolic dysfunction
Abtin, S., Ziveh, T., & Rezaee-Tavirani, M. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01729-y · Cited by 15
Crick, D. C. P., Sanderson, E. C. M., Jones, H. J., Goulding, N., Borges, M. C., Clayton, G., Carter, A. R., Halligan, S. L., Lawlor, D. A., Khandaker, G. M., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.05.033 · Cited by 13
Li, X., Yan, D., Liao, M., Zhang, L., Li, Z., Liu, B., Chen, Y., Zhang, Y., Liu, J., & Li, L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1163754 · Cited by 13
Effects of Psychosocial Stress on Subsequent Hemorrhagic Shock and Resuscitation in Male Mice
Langgartner, D., Wachter, U. A., Hartmann, C., Gröger, M., Vogt, J. A., Merz, T., McCook, O., Fink, M., Kress, S., Georgieff, M., et al. (2018) · Shock · doi:10.1097/shk.0000000000001204 · Cited by 12
Practical applications of grounding to support health
Koniver, L. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.12.001 · Cited by 12
Implementing Treatment Strategies for Different Types of Depression
McIntyre, R. S. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14077su1c.02 · Cited by 12
Li, Y., Yan, J., Zhu, X., Zhu, Y., Yao, S., Xu, Y., & Ju, S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.035 · Cited by 12
Schmidt, L. S., Petersen, J. Z., Vinberg, M., Hageman, I., Olsen, N. V., Kessing, L. V., Jørgensen, M. B., & Miskowiak, K. W. (2018) · Trials · doi:10.1186/s13063-018-2627-2 · Cited by 12
Azarfarin, M., Farajdokht, F., Babri, S., Salehpour, F., Taghizadeh, M., & Mohaddes, G. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2018.26915.6582 · Cited by 12
Systemic neuro-dysregulation in depression: Evidence from genome-wide association
Tubbs, J. D., Ding, J., Baum, L., & Sham, P. C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.08.007 · Cited by 12
Saarinen, A. I. L., Keltikangas‐Järvinen, L., Dobewall, H., Ahola‐Olli, A., Salmi, M., Lehtimäki, T. J., Raitakari, O. T., Jalkanen, S., & Hintsanen, M. (2021) · Developmental Psychobiology · doi:10.1002/dev.22070 · Cited by 14
Can precision medicine advance psychiatry?
Roche, D., & Russell, V. (2020) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2020.79 · Cited by 14
Neurotransmitter Function in Impulsive Aggression and Intermittent Explosive Disorder
Fanning, J. R., Lee, R., & Coccaro, E. F. (2020) · Wiley eBooks · doi:10.1002/9781119159322.ch10 · Cited by 11
Guan, Z., Zhang, X., Huang, W., Li, K., Chen, D., Li, W., Sun, J., Chen, L., Mao, Y., Sun, H., et al. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-024-01319-7 · Cited by 12
Leutner, M., Matzhold, C., Kautzky, A., Kaleta, M., Stefan Thurner, A., Klimek, P., & Kautzky‐Willer, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.608083 · Cited by 11
Fischer, K., Simon, M. S., Elsner, J., Dobmeier, J., Dorr, J., Blei, L., Zill, P., Obermeier, M., & Musil, R. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01245-z · Cited by 13
Marco, R. D., Barritt, A. W., Cercignani, M., Cabbai, G., Colasanti, A., & Harrison, N. A. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.04.010 · Cited by 15
Esalatmanesh, S., Kashani, L., Khooshideh, M., Moghaddam, H. S., Ansari, S., & Akhondzadeh, S. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07042-4 · Cited by 12
L’histoire de la science du stress : de Hans Selye à la découverte des anti-inflammatoires
LUPIEN, S. J. (2015) · Santé mentale au Québec · doi:10.7202/1033056ar · Cited by 11
Knapp, D. J., Harper, K. M., Melton, J., & Breese, G. R. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.06.015 · Cited by 10
the ASPREE Investigator Group, Agustini, B., Mohebbi, M., Woods, R. L., McNeil, J. J., Nelson, M. R., Shah, R. C., Murray, A. M., Ernst, M. E., Reid, C. M., et al. (2019) · CNS Drugs · doi:10.1007/s40263-019-00633-3 · Cited by 12
Brenner, P., Citarella, A., Wingård, L., & Sundström, A. (2020) · BMC Rheumatology · doi:10.1186/s41927-019-0106-3 · Cited by 11
Dittrich, K., Boedeker, K., Kluczniok, D., Attar, C. H., Winter, S., Roepke, S., Heim, C. C., Herpertz, S. C., & Bermpohl, F. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.07.024 · Cited by 11
Wadhawan, A., Dagdag, A., Duffy, A., Daue, M., Ryan, K. A., Brenner, L. A., Stiller, J. W., Pollin, T. I., Groer, M. E., Huang, X., et al. (2017) · Pteridines · doi:10.1515/pterid-2017-0019 · Cited by 11
Xu, H., Du, Y., Wang, Q., Chen, L., Huang, J., Liu, Y., Zhou, C., & Biao, D. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103394 · Cited by 12
Cepeda, Y., Elizondo-Vega, R. J., Garrido, C., Tobar, C., Araneda, M., Oliveros-Matus, P., Órdenes, P., Pardo, C. C., Vidal, P. M., Luz‐Crawford, P., et al. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1406832 · Cited by 12
Soothing liver-qi stagnation method for cancer-related depression
Zhang, J., Liu, Y., & Xu, Y. (2020) · Medicine · doi:10.1097/md.0000000000022797 · Cited by 10
Orlovska‐Waast, S., Petersen, L. V., Gasse, C., Nordentoft, M., Mortensen, P. B., Kondziella, D., & Benros, M. E. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.08.006 · Cited by 10
Self-citationMetformin is Protective Against the Development of Mood Disorders
Lake, J., Bortolasci, C. C., Stuart, A. L., Pasco, J. A., Kidnapillai, S., Spolding, B., Truong, T. T. T., Panizzutti, B., Liu, Z. S.-J., Dean, O. M., et al. (2022) · Pharmacopsychiatry · doi:10.1055/a-1936-3580 · Cited by 10
Deconstructing Diabetes and Depression: Clinical Context, Treatment Strategies, and New Directions
Gregory, J. M., Rosenblat, J. D., & McIntyre, R. S. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150040 · Cited by 11
Improvement of psychiatric symptoms in youth following resolution of sinusitis
Mahony, T., Sidell, D. R., Gans, H. A., Brown, K. D., Farhadian, B., Gustafson, M., Sherr, J., Thienemann, M., & Frankovich, J. (2016) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2016.10.034 · Cited by 10
Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
Kaur, M., & Sanches, M. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259302 · Cited by 11
C-reactive protein as a potential biomarker in psychiatric practice: Are we there yet?
Baysak, E., Güden, D. S., Arıcıoğlu, F., & Halaris, A. E. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1961502 · Cited by 10
Different Sides of Depression in the Elderly: An In-depth View on the Role of Aβ Peptides
Pagni, G., Tagliarini, C., Carbone, M. G., Imbimbo, B. P., Marazziti, D., & Pomara, N. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210921164816 · Cited by 10
Are sick people really more impulsive?: Investigating inflammation-driven impulsivity
Madison, A. A., & Kiecolt‐Glaser, J. K. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105763 · Cited by 10
Lamers, F., Milaneschi, Y., & Penninx, B. W. J. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00026-x · Cited by 12
Anti-inflammatory Intervention in Depression
Eyre, H. A., & Baune, B. T. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3128 · Cited by 10
Dinur, E., Goldenberg, H., Robinson, E., Naggan, L., Kozela, E., & Yirmiya, R. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0225 · Cited by 11
Resolving a paradox: antidepressants, neuroinflammation, and neurodegeneration
Rajkumar, R. P. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00068 · Cited by 9
A Fast-Binding, Functionally Reversible, COX‑2 Radiotracer for CNS PET Imaging
Placzek, M. S., Wilton, D. K., Weïwer, M., Manter, M. A., Reid, S. E., Meyer, C. J., Campbell, A. J., Bajrami, B., Bigot, A., Bricault, S., et al. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01564 · Cited by 9
Tang, M., Chang, X., Zheng, H., Zeng, F., Zhang, G., He, M., Fang, Q., & Yin, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1472616 · Cited by 9
Stolfi, F., Brasso, C., Raineri, D., Landra, V., Mazzucca, C. B., Ghazanfar, A., Scotti, L., Sinella, R., Villari, V., Cappellano, G., et al. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100942 · Cited by 9
Geng, C., Hao, G., Qiao, Y., Guo, Y., Chen, D., Han, W., Zhang, J., Yang, M., & Jiang, P. (2020) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106464 · Cited by 9
Hu, G., Yu, S., Yuan, C., Hong, W., Wang, Z., Zhang, R., Wang, D., Li, Z., Yi, Z., & Fang, Y. (2021) · Aging · doi:10.18632/aging.202995 · Cited by 9
Júnior, A. A. S., Alves, L. P. D. C., Padilha, B. L., & da Rocha, N. S. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221135463 · Cited by 10
Shaikh, N. F., Shen, C., LeMasters, T., Dwibedi, N., Ladani, A. P., & Sambamoorthi, U. (2023) · Cancer Informatics · doi:10.1177/11769351231165161 · Cited by 10
Xu, Y.-Q., Gou, Y.-H., Yuan, J.-J., Zhu, Y.-X., Ma, X., Chen, C., Huang, X., Yang, Z., & Zhou, Y.-M. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s436907 · Cited by 9
Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited
Lang, U. E., & Walter, M. (2017) · Neurosignals · doi:10.1159/000482001 · Cited by 9
Supporting microglial niches for therapeutic benefit in psychiatric disorders
Churchward, M. A., Michaud, E., & Todd, K. G. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109648 · Cited by 9
Inflammation, infection and depression: an evolutionary perspective
Doyle, C., Swain, W. A., Ewald, H. A. S., & Ewald, P. W. (2019) · Evolutionary Human Sciences · doi:10.1017/ehs.2019.15 · Cited by 9
Demir, E. A., Duran, G. G., Küçük, M. U., Doğan, H. D., Tutuk, O., Açıkgül, F. Ç., Bayırlı, M., Tümer, C., & Duran, N. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02831-5 · Cited by 8
Five potential therapeutic agents as antidepressants: a brief review and future directions
Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1071192 · Cited by 9
Metadata
- Authors
- Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J.
- Affiliations
- Research Department P, Aarhus University Hospital, Risskov, Denmark2Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus University Hospital, Risskov, Denmark
- University of Copenhagen (DK)
- St. George's University (GD)
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2014-12-01
- Volume
- 71
- Issue
- 12
- Pages
- 1381
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2156150528
- Semantic Scholar
- 04c60d39fcaf20a7ee393c91def9fcd0fd3f10fc
- Cited by
- 941
- References
- 56
- Citations by year
- 2026: 48 · 2025: 62 · 2024: 74 · 2023: 81 · 2022: 88 · 2021: 106 · 2020: 94 · 2019: 85 · 2018: 104 · 2017: 85 · 2016: 70 · 2015: 43 · 2014: 1
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.au.dk
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- Lundbeckfonden (R155-2014-1724)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- anti-inflammatory therapy, depression, depressive symptoms, nonsteroidal anti-inflammatory drugs, cytokine inhibitors, celecoxib, COX-2 inhibitors, antidepressant effects, adverse effects, remission, treatment response, adults with depression
- MeSH terms
- Anti-Inflammatory Agents, Depression, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
